# Aglatimagene besadenovec PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/aglatimagene-besadenovec

> The next catalyst for aglatimagene besadenovec, sponsored by Candel Therapeutics, Inc. (CADL), is its NDA/BLA submission, Q1 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, exact day, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What is the next FDA catalyst for aglatimagene besadenovec?

The next catalyst for aglatimagene besadenovec, sponsored by Candel Therapeutics, Inc. (CADL), is its NDA/BLA submission, Q1 2027. Press release filed with the SEC (EX-99): "Based on current plans and assumptions, the Company expects that its existing cash and cash equivalents will support the preparation and submission of a BLA for CAN-2409 in prostate cancer, as well as fund its current operating plan into Q1 2027." [Calendar and source filings](https://sec-api.dev/pdufa/aglatimagene-besadenovec)

Source: Press release filed with the SEC (EX-99), accession 0000950170-25-004581, https://www.sec.gov/Archives/edgar/data/1841387/000095017025004581/cadl-ex99_1.htm (retrieved 2026-11-12). Last confirmed 2026-09-10. Cite: https://sec-api.dev/pdufa/aglatimagene-besadenovec#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | aglatimagene besadenovec |
| Codes | CAN-2409 |
| Sponsor | Candel Therapeutics, Inc. (CADL) https://sec-api.dev/companies/cadl/catalysts |
| Indications | progressive, metastatic, non-squamous nsclc despite ici treatment, metastatic, non-squamous, non-small cell lung cancer, Borderline Resectable Pancreatic Adenocarcinoma |
| Modality | gene_therapy |
| FDA designations | fast track, orphan, rmat |

## Timeline

### Q4 2024: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2.
- First seen 2024-11-14, last confirmed 2024-11-14.
- Press release filed with the SEC (EX-99) (accession 0000950170-24-126759): "On track for topline progression-free survival data from the phase 2b randomized controlled clinical trial of CAN-2409 in the active surveillance population with localized low/intermediate risk prostate cancer, expected in Q4 2024" https://www.sec.gov/Archives/edgar/data/1841387/000095017024126759/cadl-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-24-126759): "Phase 2b topline data for CAN-2409 in low-to-intermediate-risk, localized, non-metastatic prostate cancer expected in Q4 2024." https://www.sec.gov/Archives/edgar/data/1841387/000095017024126759/cadl-ex99_1.htm
- SEC Form 10-Q (accession 0000950170-24-126767): "We completed enrollment of this trial in September 2021, and we expect to report topline data in the fourth quarter of 2024." https://www.sec.gov/Archives/edgar/data/1841387/000095017024126767/cadl-20240930.htm
- SEC Form 10-Q (accession 0000950170-24-126767): "We completed enrollment of this trial in May 2019, and we expect to report topline data in the fourth quarter of 2024." https://www.sec.gov/Archives/edgar/data/1841387/000095017024126767/cadl-20240930.htm

### December 11, 2024: topline data readout

- Status: completed, positive. Date confidence: exact. Stage: 3.
- First seen 2024-11-14, last confirmed 2025-03-13.
- Press release filed with the SEC (EX-99) (accession 0000950170-25-038757): "In December 2024, the Company reported positive topline data from its multicenter, randomized, placebo-controlled phase 3 clinical trial evaluating CAN-2409 in intermediate-to-high-risk localized prostate cancer patients." https://www.sec.gov/Archives/edgar/data/1841387/000095017025038757/cadl-ex99_1.htm
- SEC Form 8-K (accession 0001193125-24-274870): "On December 11, 2024, the Company announced positive topline data from its phase 3 clinical trial in the United States conducted under a SPA with the FDA evaluating patients with newly diagnosed, localized prostate cancer who have an intermediate-to-high risk for progression." https://www.sec.gov/Archives/edgar/data/1841387/000119312524274870/d901922d8k.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-24-126759): "On track for topline disease-free survival data from the phase 3 randomized controlled clinical trial of CAN-2409 in localized intermediate/high risk prostate cancer, expected in Q4 2024" https://www.sec.gov/Archives/edgar/data/1841387/000095017024126759/cadl-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-24-126759): ""We remain on track for phase 2b and phase 3 topline data in non-metastatic, localized prostate cancer for CAN-2409 in the fourth quarter of 2024, and hope we will deliver the data and regulatory approvals to enable a paradigm shift in how these patients will be treated in the future." https://www.sec.gov/Archives/edgar/data/1841387/000095017024126759/cadl-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-24-126759): "Phase 3 topline disease-free survival data for CAN-2409 in localized intermediate/high-risk prostate cancer expected in Q4 2024." https://www.sec.gov/Archives/edgar/data/1841387/000095017024126759/cadl-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-24-274870): "Expected Timing CAN-2409 ✓ Phase 3 readout for intermediate / high risk, localized prostate cancer✓ Q4'24" https://www.sec.gov/Archives/edgar/data/1841387/000119312524274870/d901922dex992.htm

### December 2025: primary completion

- Status: delayed. Date confidence: month. Stage: 2. Indication: Borderline Resectable Pancreatic Adenocarcinoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT02446093 (Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma): Overall Status UNKNOWN; Phase PHASE2; Primary Completion 2025-12 (ESTIMATED); Lead Sponsor Candel Therapeutics, Inc.." https://clinicaltrials.gov/study/NCT02446093

### Q2 2026: trial start

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: metastatic, non-squamous, non-small cell lung cancer.
- First seen 2025-11-13, last confirmed 2025-11-13.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-279072): "Company plans to initiate pivotal phase 3 clinical trial of CAN-2409 in patients with metastatic, non-squamous, non-small cell lung cancer (NSCLC) and progressive disease, despite immune checkpoint inhibitor (ICI) treatment, in Q2 2026" https://www.sec.gov/Archives/edgar/data/1841387/000119312525279072/cadl-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-279072): "The Company plans to initiate a pivotal phase 3 clinical trial of CAN-2409 in NSCLC in Q2 2026." https://www.sec.gov/Archives/edgar/data/1841387/000119312525279072/cadl-ex99_1.htm
- SEC Form 10-Q (accession 0001193125-25-279086): "Based on these positive findings, we plan to initiate a pivotal phase 3 clinical trial of CAN-2409 in patients with progressive, metastatic, non-squamous NSCLC despite ICI treatment in the second quarter of 2026." https://www.sec.gov/Archives/edgar/data/1841387/000119312525279086/cadl-20250930.htm
- SEC Form 10-Q (accession 0001193125-25-279086): "Based on current plans and assumptions, we expect that our existing cash and cash equivalents plus the proceeds from the loan and security agreement will be sufficient to fund our current operating plan into the first quarter of 2027, including the initiation of a pivotal phase 3 clinical trial of CAN-2409 in NSCLC in the second quarter of 2026." https://www.sec.gov/Archives/edgar/data/1841387/000119312525279086/cadl-20250930.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-279072): "We expect updated data on long-term survivors from our phase 2 study in NSCLC in Q1 2026 and anticipate initiation of the phase 3 study in Q2 2026." https://www.sec.gov/Archives/edgar/data/1841387/000119312525279072/cadl-ex99_1.htm

### Q1 2027: NDA/BLA submission

- Status: scheduled. Date confidence: quarter.
- First seen 2025-01-13, last confirmed 2026-09-10.
- Press release filed with the SEC (EX-99) (accession 0000950170-25-004581): "Based on current plans and assumptions, the Company expects that its existing cash and cash equivalents will support the preparation and submission of a BLA for CAN-2409 in prostate cancer, as well as fund its current operating plan into Q1 2027." https://www.sec.gov/Archives/edgar/data/1841387/000095017025004581/cadl-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-387310): ""Martine joins Candel at an important stage in our evolution, as we prepare for the planned submission of the BLA for aglatimagene besadenovec in the fourth quarter of 2026 and continue building the capabilities required of a potential commercial-stage company," said Paul Peter Tak, M.D., Ph.D., FMedSci, President and Chief Executive Officer of Candel." https://www.sec.gov/Archives/edgar/data/1841387/000119312526387310/cadl-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-347957): "Planning to submit a Biologics License Application (BLA) for aglatimagene besadenovec (aglatimagene) in localized, intermediate- to high-risk prostate cancer in Q4 2026" https://www.sec.gov/Archives/edgar/data/1841387/000119312526347957/cadl-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-222892): "Company plans to submit a Biologics License Application (BLA) for aglatimagene besadenovec (aglatimagene or CAN-2409) in localized, intermediate- to high-risk prostate cancer in Q4 2026" https://www.sec.gov/Archives/edgar/data/1841387/000119312526222892/cadl-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-279072): "Plan to submit a Biologics License Application (BLA) for CAN-2409 in intermediate-to-high-risk localized prostate cancer in Q4 2026" https://www.sec.gov/Archives/edgar/data/1841387/000119312525279072/cadl-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-108448): "He will continue to be instrumental as the Company advances its clinical pipeline and prepares for BLA submission of CAN-2409 in localized prostate cancer, anticipated in Q4 2026." https://www.sec.gov/Archives/edgar/data/1841387/000095017025108448/cadl-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-108448): "Based on current plans and assumptions, the Company expects that its existing cash and cash equivalents will be sufficient to fund operations into Q1 2027, including the Company's expected submission of the BLA for CAN-2409 in intermediate-to-high-risk prostate cancer to the FDA in Q4 2026." https://www.sec.gov/Archives/edgar/data/1841387/000095017025108448/cadl-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-145405): "The Company intends to use the net proceeds from the Offering to complete critical launch readiness, medical affairs and pre-commercialization activities, while preparing for submission of a Biologics License Application for CAN-2409 in prostate cancer expected in the fourth quarter of 2026, and for general corporate purposes." https://www.sec.gov/Archives/edgar/data/1841387/000119312525145405/d34398dex991.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-082705): ""Maha's expertise will be invaluable as we look forward to her contributions while we prepare to submit our Biologics License Application for CAN-2409 in intermediate-to-high-risk prostate cancer, anticipated in Q4 2026," said Paul B. Manning, Chairman of Candel's Board." https://www.sec.gov/Archives/edgar/data/1841387/000095017025082705/cadl-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-076458): "As we continue advancing our regulatory preparations in anticipation of submitting a Biologics License Application for CAN-2409 in the fourth quarter of 2026, our focus remains on bringing this potentially transformative treatment to patients in need of better options."" https://www.sec.gov/Archives/edgar/data/1841387/000095017025076458/cadl-ex99_1.htm
- SEC Form 10-Q (accession 0001193125-25-279086): "We are in ongoing dialogue with the FDA in preparation for the Company's anticipated submission of a Biologics License Application for CAN-2409 in prostate cancer in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1841387/000119312525279086/cadl-20250930.htm
- SEC prospectus (424B) (accession 0001193125-25-145401): "We intend to use the net proceeds we receive from this offering to complete critical launch readiness, medical affairs and pre-commercialization activities, while preparing for submission of a Biologics License Application (BLA) for CAN-2409 in prostate cancer expected in the fourth quarter of 2026, and for general corporate purposes." https://www.sec.gov/Archives/edgar/data/1841387/000119312525145401/d917630d424b5.htm

### Q1 2027: trial start

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2025-11-13, last confirmed 2025-11-13.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-279072): "Cash and cash equivalents of $87.0M, as of September 30, 2025, plus the upfront proceeds from the Trinity Capital debt facility, strengthens the Company's financial position to fund initiation of potentially registrational phase 3 trial of CAN-2409 in NSCLC and other planned operations into Q1 2027" https://www.sec.gov/Archives/edgar/data/1841387/000119312525279072/cadl-ex99_1.htm

## Same indication

- [Aglatimagene](https://sec-api.dev/pdufa/aglatimagene) (CADL)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/aglatimagene-besadenovec.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Aglatimagene besadenovec PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/aglatimagene-besadenovec

```bibtex
@misc{secapidev_pdufa_aglatimagene_besadenovec_20261116,
  title        = {Aglatimagene besadenovec PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/aglatimagene-besadenovec}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_aglatimagene_besadenovec_20261116","title":"Aglatimagene besadenovec PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/aglatimagene-besadenovec","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
